Diabetic Eye Disease Awareness

Diana Do, MD

Do reports receiving research funding from Belite Bio, Boehringer Ingelheim, Regeneron and Regenxbio; consulting for AbbVie, Apellis, Belite Bio, Iveric Bio, Kodiak Sciences, Regeneron and Regenxbio; and owning stock options in Kodiak Sciences.
March 12, 2024
1 min watch
Save

VIDEO: Socioeconomic disparities in diabetic eye disease

Transcript

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We’ve seen through multiple studies that there are disparities in health care, especially in underrepresented minorities. We’ve also seen that the prevalence of diabetes has also increased dramatically in underrepresented minorities, such as Hispanic or African American patients. And unfortunately, many of these patients have socioeconomic hardships, which may prevent them from having timely care with the ophthalmologists or retina specialists when they do have diabetic eye disease. It’s important to let these patients know, and the primary care physicians know, that timely and prompt treatment for their diabetic eye disease can prevent further damage and also can help improve their vision if they’re treated promptly and at a regular interval.